AIDS TREATMENT NEWS Issue No. 344, June 2, 2000
John S. James
A related editorial(2), "Is Academic Medicine for Sale," appeared in the same issue, and is available at http://www.nejm.org/content/2000/0342/0020/1516.asp
An example from the article:
"If a drug is tested in a healthier population (younger, with fewer coexisting conditions and with milder disease) than the population that will actually receive the drug, a trial may find that the drug relieves symptoms and creates fewer adverse effects than will actually be the case. Rochon et al. found that only 2.1 percent of subjects in trials of nonsteroidal anti-inflammatory drugs were 65 years of age or older, even though these drugs are more commonly used and have a higher incidence of side effects in the elderly... Rochon et al. concluded that trials of nonsteroidal anti- inflammatory drugs always found the sponsoring company's product superior or equal to the comparison product..."
Another section concerns the "guest-ghost syndrome," by which journal articles are increasingly ghostwritten by medical writers, based on information packets supplied to them by pharmaceutical companies--and then signed by well-known "guest authors" who did not analyze the data or write the manuscript, and sometimes were not involved in the trial at all.
And from the accompanying editorial:
"It is difficult to believe that full-time faculty members can generate outside income greater than their salaries without shortchanging their institutions and their students."
References
1. Bodenheimer T. Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. NEW ENGLAND JOURNAL OF MEDICINE May 18, 2000; volume 342, number 20, pages 1539- 1544.
2. Angell M. Is Academic Medicine for Sale? NEW ENGLAND JOURNAL OF MEDICINE May 18, 2000; volume 342, number 20, pages 1516-1518.
000602
ATN34404
Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .